Abstract

MELGAREJO-RUBIO, Guadalupe; PEREZ-TAPIA, Sonia M.; MEDINA-RIVERO, Emilio  and  VELASCO-VELAZQUEZ, Marco A.. Antibody-drug conjugates: the new generation of biotechnological therapies against cancer. Gac. Méd. Méx [online]. 2020, vol.156, n.3, pp.229-236.  Epub May 27, 2021. ISSN 2696-1288.  https://doi.org/10.24875/gmm.20005572.

Therapeutic antibodies are recombinant proteins used in the treatment of cancer. There is a new generation of monoclonal antibodies with activity against cancer cells, known as antibody-drug conjugates. These molecules are made up of three elements: a monoclonal antibody, a highly potent cytotoxic drug, and a chemical linker that binds them together. The antibody recognizes tumor antigens, thereby allowing targeted delivery of the cytotoxic agent to cancer cells. After recognizing its antigen, the antibody-drug conjugate is endocytosed by the target cells, where the protein fraction is degradated into lysosomes, releasing the cytotoxic drug. This article reviews antibody-drug conjugates general characteristics and describes the clinical evidence of efficacy and safety of the first four approved by regulatory agencies in the United States and Europe.

Keywords : Antibody-drug conjugates; Gemtuzumab ozogamicin; Brentuximab vedotin; Trastuzumab emtansine; Inotuzumab ozogamicin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )